Featured Publications
Folate metabolism in tumor-associated macrophages drives immunosuppressive function to promote tumor growth
Zimmerman MP, Zhabotynsky V, Wang H, Cox EK, Chong WL, Bastian AG, Kennedy AS, Fay BP, Reynolds AG, Ebacher A, Meier JA, Vietor K, Taylor KE, Onuoha PC, Maruvada S, Hurst KE, Wong C, Anderson CW, Thomas NE, Liu R, Bryant KL, Baldwin AS, Ollila DW, Ting JPY, Rushing BR, Sumner SJ, Krupenko SA, Hugo W, Moschos SJ, Thaxton JE, Miller BC BioXRiv preprint.
Harnessing Inflammatory Monocytes to Overcome Resistance to Anti-PD-1 Immunotherapy
Zimmerman MP, Huang AC, Cox EK, Al Abosy R, Chong WL, Bastian AG, Vietor K, Choutri Y, Collier J, Zhabotynsky V, Wang H, Fung M, Weiss SA, Robitschek EJ, Lin JR, Vallius T, Pant S, Sorger PK, Hugo W, Sen DR, Haining WN, Sharpe AH, Miller BC. J. ImmunoTher. Cancer. 2026;14:e015096. doi:10.1136/ jitc-2026-015096
PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment
Collins NB, Al Abosy R, Miller BC, Bi K, Zhao Q, Quigley M, Ishizuka JJ, Yates KB, Pope HW, Manguso RT, Shrestha Y, Wadsworth M, Hughes T, Shalek AK, Boehm JS, Hahn WC, Doench JG, Haining WN. J ImmunoTher. Cancer. 2022 Mar;10(3).
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
Miller BC*, Sen DR*, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, Manos M, Gjini E, Kuchroo JR, Ishizuka JJ, Collier JL, Griffin GK, Maleri S, Comstock DE, Weiss SA, Brown FD, Panda A, Zimmer MD, Manguso RT, Hodi FS, Rodig SJ, Sharpe AH, Haining WN. Nature Immunol. 2019 Mar; 20(3):326-336.
*These two authors contributed equally to this manuscript.
Loss of ADAR1 in tumors overcomes resistance to immune checkpoint blockade
Ishizuka JJ, Manguso RT, Cheruiyot CK, Bi K, Panda A, Iracheta-Vellve A, Miller BC, Du PP, Yates KB, Dubrot J, Buchumenski I, Comstock DE, Brown FD, Ayer A, Kohnle IC, Pope HW, Zimmer MD, Sen DR, Lane-Reticker SK, Robitschek EJ, Griffin GK, Collins NB, Long AH, Doench JG, Kozono D, Levanon EY, Haining WN. Nature. 2019 Jan; 565(7737):43-48.
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso RT, Pope HW, Zimmer MD, Brown FD, Yates KB, Miller BC, Collins NB, Bi K, LaFleur MW, Juneja VR, Weiss SA, Lo J, Fisher DE, Miao D, Van Allen E, Root DE, Sharpe AH, Doench JG, Haining WN. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017 Jul 27; 547(7664):413-418.